Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03412565
Title A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Janssen Research & Development, LLC

multiple myeloma


Bortezomib + Daratumumab + Dexamethasone + Melphalan + Prednisone

Daratumumab + Dexamethasone + Lenalidomide

Bortezomib + Daratumumab + Dexamethasone + Lenalidomide

Age Groups: senior | adult
Covered Countries USA | FRA | ESP | DEU

No variant requirements are available.